Malaria, Vivax: Clinical Trials

19 trials for Malaria, Vivax, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 3 not yet recruiting, 1 unknown. 19 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 119Completed 15, Not yet recruiting 3, Unknown 1
Phase 26Completed 4, Not yet recruiting 1, Unknown 1

Follow Malaria, Vivax: new trials by email Literature Review of Malaria, Vivax trials Research Report on Malaria, Vivax

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model
Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001, Pvs230D1-EPA/Matrix-M - Healthy Volunteers, Malaria
Phase 1 / Phase 2Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)2202026-11-232026-11-18
Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years
LYB014 low dose, LYB014 high dose, LYB017 low dose - Malaria Vaccine
Phase 1Not yet recruitingGuangzhou Patronus Biotech Co., Ltd.722026-10-012026-10-22
Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."
Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory, Placebo - Malaria Vivax
Phase 1Not yet recruitingFederal University of Minas Gerais482025-09-012025-09-15
Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1
PvDBPII/Matrix-M1 - Malaria, Vivax
Phase 1 / Phase 2CompletedUniversity of Oxford242020-01-242024-11-25
Plasmodium Immunotherapy for Lung Cancer
Blood-stage infection of P. vivax - Lung Cancer, Nonsmall Cell
Phase 1 / Phase 2UnknownState Key Laboratory of Respiratory Disease302016-06-272023-06-22
P.Vivax Treatment Trial
Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ), Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo - Plasmodium Vivax
Phase 1 / Phase 2CompletedUniversity of Oxford412016-06-142022-03-02
A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution
Tafenoquine Control, Tafenoquine dissolution profile X, Tafenoquine SIL - Malaria, Vivax
Phase 1CompletedGlaxoSmithKline142016-05-012017-01-20
Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)
Tafenoquine 150 mg, Matched placebo 150mg - Malaria, Vivax
Phase 1CompletedGlaxoSmithKline4862016-02-022018-03-01
A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate
Tafenoquine, Dihydroartemisinin + Piperaquine tetraphosphate, Artemether + Lumefantrine - Malaria, Vivax
Phase 1CompletedGlaxoSmithKline1202014-07-312017-07-13
Phase Ia Study of ChAd63/MVA PvDBP
ChAd63 PvDBP 5 x 10^9, ChAd63 PvDBP 5 x 10^10, MVA PvDBP 1 x 10^8 - Malaria, Plasmodium Vivax
Phase 1CompletedUniversity of Oxford242013-04-012017-05-08
Primaquine Pharmacokinetics in Lactating Women and Their Infants
Primaquine - Vivax Malaria
Phase 1CompletedUniversity of Oxford202012-12-012016-02-15
Exposure of Naive and Pre-immune Subjects to P. Vivax Challenge
P. vivax infected mosquito bites - Malaria
Phase 1 / Phase 2CompletedSocrates Herrera Valencia162012-10-012014-01-15
Tafenoquine Thorough QTc Study in Healthy Subjects
Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg - Malaria, Vivax
Phase 1CompletedGlaxoSmithKline2602011-07-262017-06-12
Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects
A, B - Vivax Malaria
Phase 1CompletedUniversity of Oxford162010-10-012012-06-14
Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults
VMP001, P. vivax sporozoite challenge - Malaria, Plasmodium Vivax
Phase 1 / Phase 2CompletedU.S. Army Medical Research and Development Command412010-07-012019-05-29
Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans
Malaria Challenge - Plasmodium Vivax Malaria
Phase 1CompletedU.S. Army Medical Research and Development Command122009-04-212018-08-16
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion - Malaria Falciparum, Malaria Vivax
Phase 1CompletedMedicines for Malaria Venture632009-04-012015-01-08
Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants
Peptides (N,R&C) formulated in Montanide ISA 720, Peptides (N,R&C) formulated in Montanide ISA 51, Placebo - Malaria, Vivax
Phase 1CompletedMalaria Vaccine and Drug Development Center402005-07-012010-03-08
PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
PpPfs25/ISA51 & ScPvs25/ISA51 - Plasmodium Falciparum, Plasmodium Vivax Malaria
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)2005-03-072017-07-02

Narrower conditions

Malaria (10)  ·  Malaria, Falciparum (3)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Parasitemia (1)

Broader conditions

Infections (19)  ·  Mosquito-Borne Diseases (19)  ·  Parasitic Diseases (19)  ·  Protozoan Infections (19)  ·  Vector Borne Diseases (19)  ·  Malaria (9)  ·  Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)  ·  Inflammation (1)  ·  Lung Diseases (1)  ·  Lung Neoplasms (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

tafenoquine (3)  ·  Primaquine (2)  ·  Artemether, Lumefantrine Drug Combination (1)  ·  Matrix-M (1)  ·  Moxifloxacin (1)  ·  Peptides (1)  ·  artefenomel (1)  ·  artenimol (1)  ·  mannide monooleate (1)  ·  montanide ISA 51 (1)

Sponsors

University of Oxford (5)  ·  GlaxoSmithKline (4)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  U.S. Army Medical Research and Development Command (2)  ·  Federal University of Minas Gerais (1)  ·  Guangzhou Patronus Biotech Co., Ltd. (1)  ·  Malaria Vaccine and Drug Development Center (1)  ·  Medicines for Malaria Venture (1)  ·  Socrates Herrera Valencia (1)  ·  State Key Laboratory of Respiratory Disease (1)

Countries

United States (9)  ·  Colombia (2)  ·  Thailand (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Brazil (1)  ·  China (1)  ·  Laos (1)

Top investigators

Adrian V S Hill, MD (1)  ·  Angela M Minassian, Dr (1)  ·  Ilin Chuang, MD, MPH (1)  ·  Jason Bennett, MD (1)  ·  Joerg Moehrle, PhD (1)  ·  Maria Gutierrez, MD (1)  ·  Mayfong Mayxay, MD (1)  ·  Ming Ou-Yang, M.D. (1)  ·  Myriam Arevalo-Herrera, PhD (1)  ·  Podjanee Jittamala, MD (1)  ·  Ricardo T Gazzinelli, DVM, PhD (1)  ·  Rose McGready, MD (1)  ·  Shanan R Immel, M.D. (1)

Results publications

PMID 18612426, PMID 21931708, PMID 22759078, PMID 24088113, PMID 24687509, PMID 24963662, PMID 27697758, PMID 28614791, PMID 29590311, PMID 29869298, PMID 31187437, PMID 31888643, PMID 31900172, PMID 34161579, PMID 35664997, PMID 38719803